Emerging Markets are key to the ongoing pipeline- and sales-driven transformation of AstraZeneca. Over the past years, our global sales base has changed from having most of sales coming from what we now call ‘Other’ medicines to our current setup where our business is focused on three main therapy areas: Oncology, New Cardiovascular, Renal & Metabolism, and Respiratory. In these therapy areas, Emerging Markets now outperform the rest of the world.
Year-end webcast for investors and analysts on China and Emerging Markets
On 13 December 2018, we hosted a webcast for investors and analysts on China and Emerging markets.
Quarterly sales in Emerging Markets now 1/3 of total sales
Our quarterly sales in Emerging Markets have steadily increased over the past years; from around 1 billion US dollars to more than 1.5 billion US dollars per quarter and from a bit less than 20% of sales to now more than 1/3 of sales.
Emerging Markets Strategy
We have a three-pillar strategy in Emerging Markets, which was originally built upon the China strategy of Expansion, Innovation and Partnership.
- Market access is especially critical to expansion, so we can reach more patients with our medicines in previously-inaccessible countries.
- Regarding innovation, our aim is to strongly contribute to patient-centric, fully-integrated ecosystems. We also aim to discover and develop new medicines in Emerging Markets that are fit for our patient populations in those markets.
- Partnership is more than just a word or intention – at AstraZeneca we proactively work with local and central governments and local partners. We also work closely with local healthcare providers and local capital markets where possible.
AstraZeneca in China
>$750m
Investment in discovery and development of medicines in China
1993
The year we started operating in China
>13,000
Employees in China
Shanghai
Our China Headquarters
We are proud to be present in China for over 25 years now. We have invested, and continue to invest, in local R&D and manufacturing in Taizhou and Wuxi.
We are the number two multinational in China, AstraZeneca’s second-largest market globally. Importantly, we’ve been growing faster than any other multinational company in China for several years.
